Corporate News

Cencora Inc, a pharmaceutical company, has reported financial results for the recent quarter. Key highlights from the earnings report include:

• Revenue exceeded estimates, with a notable increase in sales of GLP-1 class products
• Earnings per share (EPS) also surpassed expectations, driven by strong performance in the U.S. segment
• The U.S. segment reported a 19.8% increase in EPS, contributing to an upward revision in the company’s guidance

The company’s financial performance has led to an increase in its stock price, reaching a 52-week high. Additionally, Cencora Inc has declared a dividend of $0.55.

Financial Highlights

• Revenue: exceeded estimates
• Earnings per share (EPS): surpassed expectations
• U.S. segment EPS growth: 19.8%
• Dividend: $0.55 declared